Cargando…

PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition

The recent approval of immune checkpoint inhibitors drastically changed the standard treatments in many advanced cancer patients, but molecular changes within the tumor can prevent the activity of immunotherapy drugs. Thus, the introduction of the inhibitors of the immune checkpoint programmed death...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cretella, Daniele, Digiacomo, Graziana, Giovannetti, Elisa, Cavazzoni, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770107/ https://www.ncbi.nlm.nih.gov/pubmed/31500143 http://dx.doi.org/10.3390/cancers11091318

Ejemplares similares

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
por: Cavazzoni, Andrea, et al.
Publicado: (2020)

It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer
por: Garajová, Ingrid, et al.
Publicado: (2022)

Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN
por: Cavazzoni, Andrea, et al.
Publicado: (2017)

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
por: Jiang, Xianjie, et al.
Publicado: (2019)

New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway
por: Alfieri, Roberta, et al.
Publicado: (2017)

Role of Cytokines and Other Soluble Factors in Tumor Development: Rationale for New Therapeutic Strategies
por: Cavazzoni, Andrea, et al.
Publicado: (2023)

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2018)

PPARγ inhibited tumor immune escape by inducing PD‐L1 autophagic degradation
por: Gou, Qian, et al.
Publicado: (2023)

Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
por: Zhou, Kaijian, et al.
Publicado: (2020)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

S100a9 deficiency accelerates MDS-associated tumor escape via PD-1/PD-L1 overexpression: S100a9 deficiency accelerates tumor escape
por: Wang, Roujia, et al.
Publicado: (2023)

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020)

Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism
por: Fumarola, Claudia, et al.
Publicado: (2017)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

PB1919: S100A9 DEFICIENCY ACCELERATES MDS ASSOCIATED TUMOR ESCAPE VIA PD-1/PD-L1 OVEREXPRESSION
por: Wang, R., et al.
Publicado: (2022)

The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides
por: Grywalska, Ewelina, et al.
Publicado: (2017)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

PD-1 and PD-L1 expression in rare lung tumors
por: Gyulai, Marton, et al.
Publicado: (2023)

PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer
por: Song, Minmin, et al.
Publicado: (2013)

Role of PD-1/PD-L1-mediated tumour immune escape mechanism and microsatellite instability in the BCG failure of high-grade urothelial carcinomas
por: SALMAN, Fadime Gül, et al.
Publicado: (2022)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations
por: Sun, Xin, et al.
Publicado: (2018)

Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression
por: Pu, Yunzhou, et al.
Publicado: (2022)

PD-L1 Amino Acid Position 88 Represents a Hotspot for PD-L1 Stability With Relevance for PD-L1 Inhibition
por: Claaß, Luise Victoria, et al.
Publicado: (2022)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

PD-1 and PD-L1 expression in pulmonary carcinoid tumors and their association to tumor spread
por: Vesterinen, Tiina, et al.
Publicado: (2019)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
por: Passariello, Margherita, et al.
Publicado: (2019)

Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
por: Chu, Xianjing, et al.
Publicado: (2023)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
por: Zhang, Yiru, et al.
Publicado: (2023)

Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors
por: Fan, Yangwei, et al.
Publicado: (2016)

PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma
por: Cao, Jinfeng, et al.
Publicado: (2017)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors
por: Song, Doo-Won, et al.
Publicado: (2021)

Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance
por: Vautrot, Valentin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ll8jqmosih63qhns5j4h64ku9